The Future of RNAi Therapeutics: Drug pipelines and prospects

"The total RNAi therapy market is estimated to value $580m by 2012. This forecast is based upon current treatments, levels of market satisfaction and five new Phase II/III RNAi agents profiled in this report."

RNA interference continues to offer significant promise for a host of therapeutic treatments. Potentially any disease-causing gene, cell type or tissue can be targeted with RNAi, including those not ‘druggable’ with small molecules or protein-based therapies. Pharma companies are increasingly investing in siRNA optimization or examining siRNA alternatives, in addition to staking out proprietary positions in lipid-based, nanotransporter-based and alternative delivery technologies. The development and licensing of such platforms will become crucial for developers over the coming years. ‘The Future of RNAi Therapeutics: Drug pipelines and prospects’ is a report published by Business Insights that provides an in-depth assessment of recent progress and future opportunities for RNAi players in major therapeutic areas including infectious diseases, cancer, inflammation/immune dysfunction, CNS disorders and cardiology/metabolism. The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies and company pipelines, and the activities and strategies of 37 RNAi-based developers are profiled. This report also provides forecasts for market growth to 2012 across major RNAi market segments. Identify the developmental status of key RNAi agents, review the latest advances in RNAi technologies and assess the competitive landscape with this report’s analysis of 37 companies across major therapeutic areas.

Measure the developmental progress of 97 RNAi agents, review the latest advances in delivery technologies and evaluate 37 RNAi-based companies across major therapeutic areas...

Use this report to...

Analyze emerging RNAi agents and delivery technologies and examine new molecular targets and pipeline antisense drugs.

Evaluate 97 RNAi compounds in development for infectious and inflammatory diseases, cancer and other major disease categories.

Assess 37 competitors and potential collaborators developing RNAi technologies and examine the latest RNAi-related patenting trends.

Identify potential growth segments and develop future strategies with this report’s forecasts for the global RNAi therapy market to 2012.

Publication: 39692
Library Code: rbdd0025
Type: Report
Format: PDF
Pages: 253